Literature DB >> 21993206

Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats.

Gregory T Collins1, Diwahar Narasimhan, Alyssa R Cunningham, Matthew E Zaks, Joseph Nichols, Mei-Chuan Ko, Roger K Sunahara, James H Woods.   

Abstract

Recent mutagenesis studies have identified a mutant G4C/S10C/T172R/G173Q cocaine esterase (CCRQ CocE) with an in vitro duration of action of >40 days. Although the in vivo duration of CCRQ CocE's action was <24 h, modification of this enzyme with polyethylene glycol (PEG) polymers resulted in a CocE (PEG-CCRQ CocE) capable of preventing cocaine-induced lethality for up to 72 h. The current studies were aimed at providing a detailed characterization of the effectiveness, selectivity, and duration of PEG-CCRQ CocE's actions in cocaine self-administration and discrimination assays in rats. Pretreatment with PEG-CCRQ CocE produced dose-dependent rightward shifts in the dose-response curves for cocaine self-administration and discrimination, with the highest dose of PEG-CCRQ CocE capable of producing an initial shift of cocaine's reinforcing and interoceptive effects of >30-fold to the right, with significant inhibition of these effects observed for up to 72 h. Although PEG-CCRQ CocE also produced slight reductions in the rates of methylphenidate- and food-reinforced responding, these effects were short-lived, lasting <24 h. Finally, when taken together with the finding that PEG-CCRQ CocE failed to alter the cocaine-like interoceptive effects of either methylphenidate or d-amphetamine, these results suggest that PEG-CCRQ CocE possesses a high degree of pharmacologic specificity for cocaine and a prolonged in vivo duration of action. In conclusion, these studies provide strong evidence to support the further development of long-lasting, highly efficient CocEs, such as PEG-CCRQ CocE, as a potential therapeutic option for the treatment of cocaine abuse in humans.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993206      PMCID: PMC3306869          DOI: 10.1038/npp.2011.226

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  48 in total

1.  Cocaine esterase: interactions with cocaine and immune responses in mice.

Authors:  Mei-Chuan Ko; Luvina D Bowen; Diwahar Narasimhan; Aaron A Berlin; Nicholas W Lukacs; Roger K Sunahara; Ziva D Cooper; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2006-11-17       Impact factor: 4.030

2.  Effects of cocaine esterase following its repeated administration with cocaine in mice.

Authors:  Mei-Chuan Ko; Diwahar Narasimhan; Aaron A Berlin; Nicholas W Lukacs; Roger K Sunahara; James H Woods
Journal:  Drug Alcohol Depend       Date:  2009-02-13       Impact factor: 4.492

3.  Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats.

Authors:  Gregory T Collins; Remy L Brim; Diwahar Narasimhan; Mei-Chuan Ko; Roger K Sunahara; Chang-Guo Zhan; James H Woods
Journal:  J Pharmacol Exp Ther       Date:  2009-08-26       Impact factor: 4.030

4.  Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase.

Authors:  Ziva D Cooper; Diwahar Narasimhan; Roger K Sunahara; Pawel Mierzejewski; Emily M Jutkiewicz; Nicholas A Larsen; Ian A Wilson; Donald W Landry; James H Woods
Journal:  Mol Pharmacol       Date:  2006-09-12       Impact factor: 4.436

5.  Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity.

Authors:  Daquan Gao; Diwahar L Narasimhan; Joanne Macdonald; Remy Brim; Mei-Chuan Ko; Donald W Landry; James H Woods; Roger K Sunahara; Chang-Guo Zhan
Journal:  Mol Pharmacol       Date:  2008-11-05       Impact factor: 4.436

6.  Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans.

Authors:  Margaret Haney; Erik W Gunderson; Huiping Jiang; Eric D Collins; Richard W Foltin
Journal:  Biol Psychiatry       Date:  2010-01-01       Impact factor: 13.382

7.  Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors.

Authors:  Takato Hiranita; Paul L Soto; Amy H Newman; Jonathan L Katz
Journal:  J Pharmacol Exp Ther       Date:  2009-02-19       Impact factor: 4.030

8.  A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats.

Authors:  Stephen Brimijoin; Yang Gao; Justin J Anker; Luke A Gliddon; David Lafleur; R Shah; Qinghai Zhao; M Singh; Marilyn E Carroll
Journal:  Neuropsychopharmacology       Date:  2008-01-16       Impact factor: 7.853

9.  A bacterial cocaine esterase protects against cocaine-induced epileptogenic activity and lethality.

Authors:  Emily M Jutkiewicz; Michelle G Baladi; Ziva D Cooper; Diwahar Narasimhan; Roger K Sunahara; James H Woods
Journal:  Ann Emerg Med       Date:  2008-11-14       Impact factor: 5.721

10.  Prevention and reversal by cocaine esterase of cocaine-induced cardiovascular effects in rats.

Authors:  Susan K Wood; Diwahar Narasimhan; Ziva Cooper; Roger K Sunahara; James H Woods
Journal:  Drug Alcohol Depend       Date:  2009-10-01       Impact factor: 4.492

View more
  18 in total

1.  Maintenance of reinforcement to address the chronic nature of drug addiction.

Authors:  Kenneth Silverman; Anthony DeFulio; Sigurdur O Sigurdsson
Journal:  Prev Med       Date:  2012-06-05       Impact factor: 4.018

2.  Thinking outside the synapse: pharmacokinetic-based medications for cocaine addiction.

Authors:  Paul W Czoty; David C S Roberts
Journal:  Neuropsychopharmacology       Date:  2011-11-09       Impact factor: 7.853

3.  Repeated administration of a mutant cocaine esterase: effects on plasma cocaine levels, cocaine-induced cardiovascular activity, and immune responses in rhesus monkeys.

Authors:  Gregory T Collins; Remy L Brim; Kathleen R Noon; Diwahar Narasimhan; Nicholas W Lukacs; Roger K Sunahara; James H Woods; Mei-Chuan Ko
Journal:  J Pharmacol Exp Ther       Date:  2012-04-19       Impact factor: 4.030

Review 4.  Bacterial cocaine esterase: a protein-based therapy for cocaine overdose and addiction.

Authors:  Diwahar Narasimhan; James H Woods; Roger K Sunahara
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 5.  Accelerating cocaine metabolism as an approach to the treatment of cocaine abuse and toxicity.

Authors:  Charles W Schindler; Steven R Goldberg
Journal:  Future Med Chem       Date:  2012-02       Impact factor: 3.808

Review 6.  Biologics to treat substance use disorders: Current status and new directions.

Authors:  Marco Pravetoni
Journal:  Hum Vaccin Immunother       Date:  2016-07-21       Impact factor: 3.452

7.  Individual Differences in the Relative Reinforcing Effects of 3,4-Methylenedioxypyrovalerone under Fixed and Progressive Ratio Schedules of Reinforcement in Rats.

Authors:  Brenda M Gannon; Kayla I Galindo; Kenner C Rice; Gregory T Collins
Journal:  J Pharmacol Exp Ther       Date:  2017-02-08       Impact factor: 4.030

8.  Subunit stabilization and polyethylene glycolation of cocaine esterase improves in vivo residence time.

Authors:  Diwahar Narasimhan; Gregory T Collins; Mark R Nance; Joseph Nichols; Elin Edwald; Jimmy Chan; Mei-Chuan Ko; James H Woods; John J G Tesmer; Roger K Sunahara
Journal:  Mol Pharmacol       Date:  2011-09-02       Impact factor: 4.436

9.  Development of Fc-Fused Cocaine Hydrolase for Cocaine Addiction Treatment: Catalytic and Pharmacokinetic Properties.

Authors:  Xiabin Chen; Jing Deng; Wenpeng Cui; Shurong Hou; Jinling Zhang; Xirong Zheng; Xin Ding; Huimei Wei; Ziyuan Zhou; Kyungbo Kim; Chang-Guo Zhan; Fang Zheng
Journal:  AAPS J       Date:  2018-03-19       Impact factor: 4.009

10.  Determinants of conditioned reinforcing effectiveness: Dopamine D2-like receptor agonist-stimulated responding for cocaine-associated stimuli.

Authors:  Gregory T Collins; Charles P France
Journal:  Eur J Pharmacol       Date:  2015-11-21       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.